Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Apr 20;17(4):e0011238.
doi: 10.1371/journal.pntd.0011238. eCollection 2023 Apr.

Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study

Léa Jaume  1 , Estelle Hau  1 , Gentiane Monsel  2 , Antoine Mahé  3 , Antoine Bertolotti  4 , Antoine Petit  1 , Britney Le  5 , Marie Chauveau  6 , Elisabeth Duhamel  7 , Thierry Maisonobe  8 , Martine Bagot  1 , Jean-David Bouaziz  1   5 , Faïza Mougari  9 , Emmanuelle Cambau  9 , Marie Jachiet  1   5 ; Groupe d’infectiologie en dermatologie et des infections sexuellement transmissibles (GrIDIST)
Affiliations
Multicenter Study

Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study

Léa Jaume et al. PLoS Negl Trop Dis. .

Abstract

Introduction: Leprosy reactions (LRs) are inflammatory responses observed in 30%-50% of people with leprosy. First-line treatment is glucocorticoids (GCs), often administered at high doses with prolonged courses, resulting in high morbi-mortality. Methotrexate (MTX) is an immunomodulating agent used to treat inflammatory diseases and has an excellent safety profile and worldwide availability. In this study, we describe the efficacy, GCs-sparing effect and safety of MTX in LRs.

Methods: We conducted a retrospective multicentric study in France consisting of leprosy patients receiving MTX for a reversal reaction (RR) and/or erythema nodosum leprosum (ENL) since 2016. The primary endpoint was the rate of good response (GR) defined as the complete disappearance of inflammatory cutaneous or neurological symptoms without recurrence during MTX treatment. The secondary endpoint was the GCs-sparing effect, safety and clinical relapse after MTX discontinuation.

Results: Our study included 13 patients with LRs (8 men, 5 women): 6 had ENL and 7 had RR. All patients had had at least one previous course of GCs and 2 previous treatment lines before starting MTX. Overall, 8/13 (61.5%) patients had GR, allowing for GCs-sparing and even GCs withdrawal in 6/11 (54.5%). No severe adverse effects were observed. Relapse after MTX discontinuation was substantial (42%): the median relapse time was 5.5 months (range 3-14) after stopping treatment.

Conclusion: MTX seems to be an effective alternative treatment in LRs, allowing for GCs-sparing with a good safety profile. Furthermore, early introduction during LRs may lead to a better therapeutic response. However, its efficacy seems to suggest prolonged therapy to prevent recurrence.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of patients in the study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Maymone MBC. Leprosy: Clinical aspects and diagnostic techniques. J AM ACAD DERMATOL. 2020;83(1):14. doi: 10.1016/j.jaad.2019.12.080 - DOI - PubMed
    1. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. avr 2006;19(2):338–81. doi: 10.1128/CMR.19.2.338-381.2006 - DOI - PMC - PubMed
    1. Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol. oct 2014;71(4):795–803. - PubMed
    1. Lockwood DNJ, Lucas SB, Desikan KV, Ebenezer G, Suneetha S, Nicholls P. The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol. mai 2008;61(5):595–600. doi: 10.1136/jcp.2007.053389 - DOI - PubMed
    1. Fonseca AB de L, Simon M do V, Cazzaniga RA, de Moura TR, de Almeida RP, Duthie MS, et al.. The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy. Infect Dis Poverty. 6 févr 2017;6(1):5. doi: 10.1186/s40249-016-0229-3 - DOI - PMC - PubMed

Publication types